Literature DB >> 10733463

May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?

O Turriziani, P Di Marco, G Antonelli, F Dianzani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10733463      PMCID： PMC89711          DOI： 10.1128/AAC.44.2.473-474.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  13 in total

1.  Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein.

Authors:  G Antonelli; O Turriziani; M Cianfriglia; E Riva; G Dong; A Fattorossi; F Dianzani
Journal:  AIDS Res Hum Retroviruses       Date:  1992-10       Impact factor: 2.205

Review 2.  Multidrug resistance associated with overexpression of MRP.

Authors:  S P Cole; R G Deeley
Journal:  Cancer Treat Res       Date:  1996

3.  Induction of the multidrug-transporter P-glycoprotein by 3'-azido-3'-deoxythymidine (AZT) treatment in tumor cell lines.

Authors:  C Signoretti; G Romagnoli; O Turriziani; G Antonelli; F Dianzani; M Cianfriglia
Journal:  J Exp Clin Cancer Res       Date:  1997-03

4.  Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture.

Authors:  K D Bunting; J Galipeau; D Topham; E Benaim; B P Sorrentino
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

5.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

6.  A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent.

Authors:  B L Robbins; M C Connelly; D R Marshall; R V Srinivas; A Fridland
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

7.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.

Authors:  C B Washington; G E Duran; M C Man; B I Sikic; T F Blaschke
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-11-01

9.  Human immunodeficiency virus I-induced expression of P-glycoprotein.

Authors:  S Gollapudi; S Gupta
Journal:  Biochem Biophys Res Commun       Date:  1990-09-28       Impact factor: 3.575

10.  Zidovudine induces the expression of cellular resistance affecting its antiviral activity.

Authors:  F Dianzani; G Antonelli; O Turriziani; E Riva; E Simeoni; C Signoretti; S Strosselli; M Cianfriglia
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205
View more
  3 in total

1.  P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.

Authors:  Chiara Agrati; Fabrizio Poccia; Simone Topino; Pasquale Narciso; Cinzia Selva; Leopoldo Paolo Pucillo; Gianpiero D'Offizi; Guido Antonelli; Francesca Bellomi; Ombretta Turriziani; Federica Bambacioni
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

2.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

3.  An in-silico evaluation of COVID-19 main protease with clinically approved drugs.

Authors:  Wafa Tachoua; Mohamed Kabrine; Mamona Mushtaq; Zaheer Ul-Haq
Journal:  J Mol Graph Model       Date:  2020-09-21       Impact factor: 2.518
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.